Study helps identify which populations of foreign-born persons living in US at higher risk of TB

"From 1993 to 2006, the number of tuberculosis (TB) cases in the United States decreased by 45 percent, from 25,107 to 13,779. This decline has occurred disproportionately among the U.S.-born population, for whom the number of cases has declined by 66 percent, while the number of TB cases among foreign-born persons in the United States increased by 5 percent," the authors write. "In 2006, 57 percent of all reported TB cases were among foreign-born persons." They add that current TB control strategies have not sufficiently addressed the high levels of TB disease and latent TB infection (LTBI; TB that is not active, or infectious) in this population.

Kevin P. Cain, M.D., of the Centers for Disease Control and Prevention, Atlanta, and colleagues conducted a study to examine which populations of foreign-born persons in the U.S. are at higher risk of TB and drug-resistant TB. The researchers analyzed data of foreign-born persons in the United States diagnosed with TB from 2001 through 2006.

A total of 46,970 cases of TB disease were reported among foreign-born persons in the U.S. from 2001 through 2006, of which 12,928 (28 percent) were among recent entrants (within 2 years of U.S. entry). Among the foreign-born population overall, TB case rates declined with increasing time since U.S. entry, but remained higher than among U.S.-born persons (more than four times higher in 2006), even more than 20 years after arrival. An average of 4,035 TB cases per year were reported among individuals born in high-risk countries (populations with annual case rates of 100 or greater per 100,000 persons among recent entrants).

Among recent entrants who were culture-positive for TB, isoniazid (antibacterial drug used to treat TB) resistance was found in 20 percent from Vietnam, 18 percent from Peru, 17 percent from the Philippines and 16 percent from China.

Individuals born in most countries of sub-Saharan Africa had annual case rates of greater than 250 per 100,000 persons during the first 2 years after U.S. entry, while individuals born in Central America, Eastern Europe, the Pacific Islands, and South, East, and Central Asia had annual case rates of greater than 100 per 100,000 persons in the first 2 years. On average, 250 individuals per year were diagnosed with smear-negative, culture-positive TB disease within 3 months of U.S. entry; 46 percent of these were from the Philippines or Vietnam.

"With more than 37 million foreign-born persons currently living in the United States, it is not possible to find and test all foreign-born persons for LTBI. This study assists in targeting LTBI screening efforts by examining risk of TB disease among subgroups of foreign-born populations. Finding and treating LTBI among some specific groups of foreign-born persons living in the United States is likely to provide high yield relative to some other TB control strategies. Given current immigration patterns, the impact of culture-enhanced overseas screening of immigrants and refugees is likely be greatest in the Philippines and Vietnam, but may have limited yield for most other countries of birth," the authors write.

"Current strategies for TB control, as presently implemented, are not adequate for achieving TB elimination in the near future. TB control and elimination among foreign-born persons in the United States will require a multifaceted approach. In the future, preventing TB disease among legal immigrants to the United States might best be accomplished through overseas diagnosis and treatment of LTBI prior to immigration. The present use of a 9-month regimen for LTBI treatment makes this strategy impractical. This strategy may be both feasible and high yield when shorter, effective treatment regimens for LTBI become available. Increased investment in global TB control could also result in decreases in U.S. TB rates."

Source: JAMA and Archives Journals

Researchers identify genes associated with increased gout risk
A team of researchers from the United States and the Netherlands has identified mutations in three genes that are associated with high levels of uric acid in the blood, which is a risk factor for gout. The team developed a genetic risk score composed of the number of uric acid-increasing mutations that each person carries (0 to 6), which was associated with up to a 40-fold increased risk for developing gout when comparing persons at lowest and highest risk. The findings are published in the October 4 issue of The Lancet.
Scientists pinpoint genetic driver of narcolepsy
Scientists in Japan have identified a genetic mutation linked to narcolepsy, a disease that can cause someone to doze off in mid-sentence or behind the wheel of a car, a study released Sunday reports.
New gene variant identified for nondiabetic end stage renal disease in African-Americans
Scientists at Johns Hopkins schools of Public Health and Medicine have, for the first time, identified variants in the gene MYH9 that are associated with increased risk for non-diabetic end stage renal disease (ESRD,) which is the near-loss of kidney function leading to either dialysis of transplant. MYH9, located on the 22 chromosome, is the first gene identified for common forms of kidney disease. The study was published online September 14 in the journal Nature Genetics and will be published in the October print edition. In a separate study published in the same issue, researchers at the National Institutes of Health reported similar findings.
Vitamin B12 may protect the brain in old age
Vitamin B12, a nutrient found in meat, fish and milk, may protect against brain volume loss in older people, according to a study published in the September 9, 2008, issue of Neurology, the medical journal of the American Academy of Neurology.
Gustav becomes 'dangerous' as it bears down on Cuba
Hurricane Gustav swelled into a "dangerous" category three hurricane Saturday as it bore down on Cuba after ripping through the Cayman Islands, Dominican Republic, Haiti and Jamaica, killing 85 people.
FDA approves first drug for Huntington's disease
The U.S. Food and Drug Administration today approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Researchers to study lyme-like illness in Texas
Tao Lin, D.V.M., and Steven J. Norris, Ph.D., both with the Department of Pathology and Laboratory Medicine at The University of Texas Medical School at Houston, have been named grant recipients of the Norman Hackerman Advanced Research Program (ARP) by the Texas Higher Education Coordinating Board. They will receive $150,000 over two years to support their research into conflicting reports about the infectious nature and causative agent of Southern-Tick Associated Rash Illness (STARI) in Texas and other southern states.
Extensively drug-resistant tuberculosis found in California
In the first statewide study of extensively drug-resistant tuberculosis (XDR TB) in the United States, California officials have identified 18 cases of the dangerous and difficult-to-treat disease between 1993 and 2006, and 77 cases that were one step away from XDR TB. The study appears in the August 15 issue of Clinical Infectious Diseases, now available online.

Study helps identify which populations of foreign-born persons living in US at higher risk of TB

Related stories:

News discussion: